NDAC meetings
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription drugs advisory panel will meet jointly with the Dermatologic & Ophthalmic committee to "discuss what should be the necessary and sufficient safety database in order to evaluate the [Rx-to-OTC] switch of topical corticosteroids, especially the database to evaluate the potential for hypothalamic, pituitary, adrenal (HPA) and growth suppression and other systemic and local adverse reactions." The committee will convene at the Washington D.C. Hilton on March 24 from 8 am-5:30 pm, with the hour between 1 pm-2 pm reserved for public comment. NDAC will hold a separate meeting on March 23 to evaluate "microbiologic surrogate endpoints used to demonstrate the effectiveness of antiseptic products used in health care settings"...
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.